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328 Abstract 
29 Objective: Acromegaly is characterized by an excess of growth hormone (GH) and insulin 
30 like growth-factor 1 (IGF1). Cardiovascular disease (CVD) risk factors are common in 
31 acromegaly and often persist after treatment. Both acute and long-lasting pro-inflammatory 
32 effects have been attributed to IGF1. Therefore, we hypothesized that inflammation persists in 
33 treated acromegaly and may contribute to CVD risk. 
34 Methods: In this cross-sectional study, we assessed cardiovascular structure and function, and 
35 inflammatory parameters in treated acromegaly patients. Immune cell populations and 
36 inflammatory markers were assessed in peripheral blood from 71 treated acromegaly patients 
37 (with controlled or uncontrolled disease) and 41 matched controls. Whole blood (WB) was 
38 stimulated with Toll-like receptor ligands. In a subgroup of 21 controls and 33 patients with 
39 controlled disease, vascular ultrasound measurements were performed. 
40 Results: Leukocyte counts were lower in patients with controlled acromegaly compared to 
41 patients with uncontrolled acromegaly and controls. Circulating IL-18 concentrations were 
42 lower in patients; concentrations of other inflammatory mediators were comparable with 
43 controls. In stimulated WB, cytokine production was skewed towards inflammation in 
44 patients, most pronounced in those with uncontrolled disease. Vascular measurements in 
45 controlled patients showed endothelial dysfunction as indicated by a lower flow-mediated 
46 dilatation/nitroglycerine-mediated dilatation ratio. Surprisingly, pulse wave analysis and pulse 
47 wave velocity, both markers of endothelial dysfunction, were lower in patients, whereas 
48 intima-media thickness did not differ. 
49 Conclusions: Despite treatment, acromegaly patients display persistent inflammatory changes 
50 and endothelial dysfunction, which may contribute to CVD risk and development of CVD.
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451 Introduction
52 Acromegaly is caused by overproduction of growth hormone (GH), in most cases by a 
53 pituitary adenoma. GH in turn induces production of insulin-like growth factor 1 (IGF1) (1). 
54 Both GH and IGF1 have numerous metabolic and trophic effects (2). Apart from disease-
55 specific complications, patients with active acromegaly suffer from an increased morbidity 
56 and mortality due to cardiovascular disease (CVD) (3, 4). With disease control (i.e. 
57 normalized circulating GH and IGF1 concentrations), the increased prevalence of CVD 
58 normalizes to a great extent (5). However, the prevalence of CVD risk factors as hypertension 
59 and diabetes mellitus (DM) remains elevated (6-8), which implies persistence of the elevated 
60 CVD risk in controlled acromegaly patients. The cause of this phenomenon is incompletely 
61 understood, and it is debated whether it could be attributed to direct deleterious effects of GH 
62 and IGF1 on the cardiovascular system or is also caused by concomitant cardiovascular and 
63 metabolic disturbances that cause hypertension, insulin resistance and dyslipidemia in 
64 acromegaly patients (6).
65 Interestingly, CVD is strongly associated with subclinical systemic inflammation (9, 10). 
66 Vascular wall inflammation is an important driver of the initiation and progression of 
67 atherosclerosis, which is the main pathophysiological process driving CVD. Circulating 
68 immune cells invade the vasculature, and induce expression of adhesion molecules and 
69 subsequent leukocyte adherence, which promotes a pro-inflammatory and pro-atherogenic 
70 environment. Although the importance of innate immune cells in the development and 
71 progression of atherosclerosis is widely accepted, the unresolving character of the low-grade 
72 inflammation that drives it remains poorly understood. Recently, our group described that 
73 innate immune cells can develop long-term functional reprogramming characterized by 
74 hyperresponsiveness, termed ‘trained immunity’ (11). Short-term exposure to stimuli can 
75 induce a long-term pro-inflammatory phenotype of monocyte-derived macrophages (12, 13), 
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576 and circulating monocytes obtained from patients with risk factors for atherosclerosis or 
77 established atherosclerosis display a pro-inflammatory phenotype (14, 15). 
78 Intriguingly, immune cells express GH and IGF1 receptors (16, 17). Previously, we found that 
79 IGF1 can impact on monocyte inflammatory function in vitro (18). Moreover, exposure to 
80 IGF1 induces trained immunity (19). However, studies on the inflammatory profile of 
81 acromegaly patients rendered conflicting results: both unaltered as well as pro-inflammatory 
82 phenotypes have been reported (20-22). On the other hand, previous studies on the risk of 
83 CVD in (treated) acromegaly imply that the arterial structure and function of patients with 
84 acromegaly is impaired, which might contribute to the development of CVD (6). We therefore 
85 hypothesized that treated acromegaly patients are characterized by prolonged inflammatory 
86 changes, which might contribute to the persistence of CVD risk factors and development of 
87 CVD. To test this hypothesis, we comprehensively assessed vascular structure and function, 
88 circulating inflammatory markers and ex vivo cytokine production capacity in acromegaly 
89 patients and healthy controls. By including both patients with active disease under treatment 
90 and controlled disease, we aimed to elucidate whether these properties are reversible after 
91 disease control. 
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692 Materials and Methods
93 This cross-sectional case-control study was conducted in an academic referral center 
94 (Radboudumc Nijmegen, the Netherlands). The study structure is displayed in Figure 1.
95  
96 Subjects
97 Seventy-one adult patients with acromegaly and forty-one healthy controls (Table 1) were 
98 included between February 2016 and April 2017. All patients that were currently treated at 
99 our center or were treated within the last 5 years were selected. Subjects with inflammatory 
100 comorbidities, active malignancies or those using statins or systemic immunosuppressive 
101 medication were excluded. In addition, we excluded patients with inadequately treated 
102 hypertension (systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg), 
103 poorly controlled DM (HbA1c >69 mmol/mol for >1 year) or ischemic cardiovascular 
104 diseases, or with an alcohol intake of >21 IU per week. Non-pregnant adults with established 
105 and treated acromegaly were asked to participate (N=101), 29 patients declined. Reasons for 
106 decline were not being able to travel to the hospital, lack of time, and difficulties with being 
107 fasted. The remaining 72 patients were enrolled in the study. One patient was excluded 
108 because a previously unknown inflammatory disorder manifested during the study.
109 In order to provide a sex-, age- and body composition-matched control group, patients were 
110 asked to provide a healthy volunteer from their own living environment with, preferably, a 
111 similar age, sex, and physique. The above-mentioned criteria, except for the presence of 
112 acromegaly, were also applied to controls. In addition, controls with hormonal disturbances, 
113 except for adequately supplemented primary hypothyroidism (based on normal TSH-levels 
114 after suppletion for >3 months), were excluded. Forty-four controls were willing to 
115 participate; three candidates were excluded based on above-mentioned exclusion criteria.
116 All patients had a history of biochemically and radiologically confirmed acromegaly, defined 
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7117 as an increased serum IGF1 level (>2 SD above the mean corrected for sex and age) and 
118 insufficient suppression of serum GH levels (≥0.4 µg/l) during an oral glucose tolerance test 
119 (OGTT) (1), combined with the presence of a pituitary adenoma on a MRI- or CT-scan. All 
120 patients had received treatment (i.e. surgery, radiotherapy and/or medication; Table 2). 
121 Disease duration was based on patients’ reports that were obtained during a thorough medical 
122 history. Patients were considered cured if their serum IGF1 level fell within the reference 
123 range for sex and age, and when patients had a sufficient suppression of serum GH levels 
124 during an OGTT (GH <0.4 µg/l), that was performed after surgery and/or radiation therapy 
125 (23). Biochemical control was defined as IGF1 levels in the reference range for sex and age 
126 with use of GH or IGF1 lowering therapy. Both cured and biochemically controlled patients 
127 were considered controlled patients. Uncontrolled patients had elevated IGF1 levels despite 
128 medical, surgical and/or radiation treatment. 
129 Adrenal insufficiency was defined as an insufficient response (serum cortisol levels <0.55 
130 µmol/l) during an insulin tolerance test or a 250 μg ACTH (Synacthen) stimulation test (24), 
131 that has been performed in each patient prior to study participation following the standard of 
132 care in our hospital. Hypogonadism in premenopausal women was defined as the presence of 
133 secondary amenorrhea combined with estrogen values below the reference range. The 
134 physiological postmenopausal state, defined as gonadotrophin levels that fall in the 
135 postmenopausal range, was not considered as hypogonadism. In men, hypogonadism was 
136 defined as a testosterone level below the reference range (<11 nmol/l). Patients with hormonal 
137 deficiencies were all on stable substitution therapy, except for postmenopausal women. 
138 Testosterone respectively thyroid hormone substitution therapy was monitored with serum 
139 testosterone respectively fT4 levels.
140 In a subgroup of 21 controls and 33 patients, vascular measurements were performed. 
141 Because our study focused on the persistent long-term risk of CVD in patients with 
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8142 acromegaly, only controlled patients were included in the vascular analysis. The group of 
143 controlled patients was divided intro cured and biochemically controlled patients, given the 
144 potential beneficial effects of SSA on vascular function (25). Furthermore, to avoid potential 
145 interference with our results, only patients without hormonal deficiencies (except for diabetes 
146 insipidus), were selected.
147 This study was conducted in accordance with the Declaration of Helsinki and approved by our 
148 local ethical committee (CMO regio Arnhem-Nijmegen; 2015-2023). All subjects signed 
149 informed consent prior to participation.
150
151 Anthropometric measurements
152 Blood pressure and heart rate were measured in supine position on both arms after at least 10 
153 minutes of rest. Height, weight, waist and hip circumference were determined between 0830 
154 and 1030 h in a fasted state. All measurements were performed by a single non-blinded 
155 investigator.
156
157 Circulating inflammatory and cardiovascular markers
158 Venous blood was drawn from the brachial vein in a fasted state, between 0800 and 1000 h, in 
159 10 ml EDTA tubes (Vacutainer, BD; Franklin Lakes, NJ, USA). Within 3 hours, tubes were 
160 centrifuged (Hettich Rotina 420R, radius 183mm; 3800 RPM (RCF 2954), 10 minutes, room 
161 temperature), and plasma was collected and stored at −80°C until assayed. Plasma IGF1 
162 levels were determined by a chemiluminescent immunometric assay (Liaison, DiaSorin, 
163 Saluggia, Italy) according to the 1st WHO International Standard for Insulin-like Growth Factor-I 
164 (NIBSC code: 02/25). Levels of total cholesterol, LDL cholesterol, HDL cholesterol, non-HDL 
165 cholesterol and triglycerides were determined using an in-house analyzer (Cobas 8000; Roche 
166 Diagnostics, IN, USA).
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9167 Plasma E-Selectin, Matrix Metalloproteinase (MMP)2, vascular cell adhesion molecule 
168 (VCAM)1, high sensitivity C-Reactive Protein (hsCRP), interleukin (IL)18, IL18 binding 
169 protein (IL18BP) and IL6 levels were determined with enzyme-linked immunosorbent assays 
170 (ELISA). For E-Selectin, MMP2, VCAM1, hsCRP, and IL18, DuoSet ELISA (R&D Systems, 
171 Abingdon, United Kingdom) was used with a sensitivity of 93.8 pg/ml for E-Selectin, 625 
172 pg/ml for MMP2, 15.6 pg/ml for VCAM1 and hsCRP, and 11.7 pg/ml for IL18. For 
173 measurement of IL6 and IL18BP, high sensitivity Quantikine ELISA assays (R&D) were 
174 used with a sensitivity of 0.11 pg/ml for IL6 and 7.52 pg/ml for IL18BP.
175
176 Cell counts
177 Cell counts were obtained in fresh EDTA blood with a Sysmex automated hematology 
178 analyzer (XN-450; Sysmex Corporation, Kobe, Japan).
179
180 Ex-vivo stimulation of whole blood (WB). 
181 E. coli lipopolysaccharide (LPS; serotype 055:B5) was purchased from Sigma-Aldrich (St. 
182 Louis, MO, USA), repurified as previously described, and used as an ultrapure Toll-like 
183 receptor 4 ligand (26). Phytohemagglutinin (PHA) was purchased from Sigma-Aldrich (PHA-
184 P; L1668). Candida albicans (C.albicans) ATCC MYA-3573 (UC 820) and Staphylococcus 
185 aureus (S.aureus) Rosenbach ATCC 25923 were used. C.albicans and S.aureus were grown 
186 overnight at 37°C in Sabouraud and Brain Heart Infusion broth, respectively. Microorganisms 
187 were harvested by centrifugation, washed twice, and resuspended in Roswell Park Memorial 
188 Institute (RPMI) 1640 culture medium (Dutch Modification, Gibco, Thermo Scientific, 
189 Waltham, MA, USA) (27). C.albicans yeasts were heat-killed for 30 minutes at 95°C. 
190 Venous blood was drawn from the brachial vein in a fasted state, between 0800 and 1000 h, in 
191 4 ml lithium-heparin tubes (Vacutainer). Within three hours, 100 μl of WB was incubated at 
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192 37°C in round-bottom 48-well plates (Greiner; Kremsmünster, Austria) with 400 μl of 
193 stimulus (LPS 100 ng/ml, PHA 10 µg/ml, C.albicans 1x106/ml, S.aureus 1x106/ml) or RPMI 
194 (basal unstimulated condition) per well. After 48 hours of incubation, supernatants were 
195 collected and stored at −20°C until assayed. 
196 Cytokine concentrations were measured in supernatants by commercial ELISA kits according 
197 to the manufacturer’s instructions: tumor necrosis factor alpha (TNFa), IL1B, IL1 receptor 
198 antagonist (IL1Ra), IL6 (DuoSet ELISA, R&D), IL10, interferon gamma (IFNg) (PeliKine 
199 Compact, Sanquin; Amsterdam). The sensitivity of the assays was 2.34 pg/ml for IL10, 3.9 
200 pg/ml for IL1B and IFNg, 4.7 pg/ml for IL6, 7.8 pg/ml for TNFa, and 39.0 pg/ml for IL1Ra. 
201 The inter-assay coefficients of variability were 9.5% for IL10, 5.6% for IL1B, 12.8% for 
202 IFNg, 8.9% for IL6, 6.9% for TNFa, and 8.4% for IL1Ra.
203 All samples were analyzed in the same batch without previous freeze-thaw cycles.
204
205 Vascular measurements
206 Subjects that underwent vascular measurements refrained from exercise and consumption of 
207 caffeine, alcohol, dark chocolate, vitamin C-rich products and vitamin supplements for 24 
208 hours and fasted for at least six hours. All vascular measurements were performed between 
209 0900 and 1200 h in a supine position after at least 15 minutes of rest under standardized 
210 conditions in a temperature-controlled room (28, 29).
211
212 Pulse wave velocity and pulse wave analysis 
213 Pulse wave velocity (PWV) and pulse wave analysis (PWA) measurements were performed 
214 with a SphygmoCor EM3 tonometry device (AtCor Medical, Sydney, Australia) by a single 
215 investigator according to the manufacturer’s instructions.
216
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217 Heart Rate Corrected Central Augmented Pressure (C_AP_HR75) was calculated based on 
218 PWA of the right radial artery, the median of 3 measurements was used for data analysis. For 
219 calculation of PWV, 80% of the direct distance between the palpation site of the right 
220 common carotid and the right femoral artery was divided by the pulse transit time (in 
221 seconds) (30). 
222
223 Ultrasound measurements
224 All ultrasound measurements were performed by a single technician on a Terason t3000 
225 ultrasound device (Aloka, UK). All ultrasound images were analyzed by a single observer 
226 using computer-assisted analysis with edge-detection and wall-tracking software (DICOM 
227 Encoder Analysis Combo) (28).
228
229 Flow-mediated dilation (FMD)
230 FMD (% diameter change: (peak diameter – baseline diameter)/baseline diameter) and shear 
231 rate (Arbitrary Units; AU) were measured in the distal third of the brachial artery of the right 
232 arm using high-resolution B-mode 10 MHz ultrasonography and simultaneous acquisition of 
233 pulsed-wave Doppler velocity signals according to a validated protocol (28, 29).
234
235 Nitroglycerine-mediated dilation (NMD)
236 One minute prior and ten minutes after 0.4 mg nitroglycerine sublingually, brachial artery 
237 diameter and blood flow velocity were measured and analyzed following the same protocol as 
238 was used for FMD analysis. 
239
240 Intima-media thickness (IMT) 
241 IMT was measured using high-resolution B-mode 10 MHz ultrasonography in the common 
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242 carotid artery on the far wall, at three different angles (31). IMT was identified as the region 
243 between the lumen-intima border and the media-adventitia border. Regions of interest were 
244 manually marked and at least 50 frames per scan were analyzed to gain a representative mean 
245 of lumen diameter and IMT. These analyses were randomly repeated in order to retain 
246 accuracy. Mean IMT was calculated from at least 40 useful frames at three different angles.
247
248 Statistical analysis
249 Data were analyzed with SPSS 25.0. Data are presented as unadjusted means with SD or 
250 medians with minimum and maximum values for continuous variables, depending on the 
251 normality of the distribution, which was tested by the Shapiro-Wilk test. Differences between 
252 patients and controls were tested with an independent samples T-test or a Mann-Whitney U-
253 test (depending on the normality of the distribution) for continuous parameters and with the 
254 Fisher Exact test in case of categorical data. Differences between subgroups were tested using 
255 ANOVA. Group matching of patients and controls was performed by testing for differences in 
256 age, gender, and Body Mass Index (BMI).
257 Data on cytokines and circulating parameters was log-transformed using the natural logarithm 
258 prior to analysis with ANCOVA; BMI, age, and leukocyte count were associated with 
259 cytokine production and circulating parameters and were therefore included as covariates. For 
260 leukocyte counts, IGF1 levels, BMI and age were used. We performed a sensitivity analysis 
261 using forward selection, by alternately adding estrogen depletion, use of antihypertensives 
262 and presence of diabetes mellitus as covariates to our ANCOVA-model, which did not 
263 improve goodness of fit of the model.
264 For vascular ultrasound and PWV, age and systolic blood pressure were used as covariates 
265 (32, 33) and for C_AP_HR75, sex and systolic blood pressure were used. Correlations were 
266 determined on non-transformed data using Spearman rank correlation. All tests were two-
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267 tailed. P-values of <0.05 were considered statistically significant. When comparing three 
268 groups of subjects, the Bonferroni correction for multiple testing was applied, which rendered 
269 an adjusted P-value of 0.0167; corrected P-values were displayed.
270
271 Results
272 Subject characteristics – total group (inflammatory parameters; Table 1 and 2)
273 Of the 71 patients, 60 were controlled (of whom 32 were cured and 28 biochemically 
274 controlled), and 11 uncontrolled. The prevalence of hormonal deficiencies differed between 
275 patients and controls, but not between the subgroups. Sex, age and anthropometrical 
276 measurements were not statistically different between the total patient group and controls, 
277 which indicates adequate group matching regarding these parameters. Use of antihypertensive 
278 medication was more prevalent in patients, but blood pressure did not differ between patients 
279 and controls nor between patient subgroups. DM was not present in controls, but was present 
280 in eight patients; all but one had a HbA1c<58 mmol/mol (median 53 (40-69)). None of the 
281 subjects had established coronary artery disease. The control group contained more current 
282 smokers and the patient group more former smokers.
283 In the subgroup analysis, we observed that uncontrolled patients were younger, and had a 
284 higher weight and BMI. Disease duration tended to be shorter in uncontrolled patients, 
285 although this difference was not statistically significant. All other features were similar in 
286 both patient subgroups (Table 2). 
287
288 Subject characteristics – subgroup selected for vascular measurements 
289 Thirty-three controlled patients without hormonal deficiencies and 21 healthy controls 
290 underwent additional vascular measurements. They were comparable to the subjects of the 
291 total group, except that the patients in this subgroup used slightly more antihypertensive 
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292 drugs. However, including use of antihypertensive medication in our model did not change 
293 our results.
294
295 IGF1 levels
296 There was no difference between the plasma IGF1 levels of controlled patients (17.6±4.1 
297 nmol/l) and controls (17.3±5.4 nmol/l; P=0.7). Uncontrolled patients had higher IGF1 levels 
298 (32.6±6.9 nmol/l) than the other two groups (P<0.001).
299
300 Cell counts (Figure 2)
301 Total leukocyte count was lower in patients (5.38 (3.36-12.06) x109/l) compared to controls 
302 (6.81 (3.66-11.62) x109/l; P<0.001), as were monocyte, lymphocyte and neutrophil counts. 
303 However, the lower leukocyte count was triggered only by the controlled patients, while the 
304 leukocyte count in uncontrolled patients (7.24 (4.68-8.63) x109/l) was not different compared 
305 to controls. Relative leukocyte counts did not differ between patients and controls. The 
306 inflammatory marker neutrophil-to-lymphocyte (NtL) ratio did not differ between groups, 
307 whereas its analogue, the platelet-to-lymphocyte (PtL) ratio was higher in patients compared 
308 to controls (158.2 (62.5-365.2) vs. 137.6 (74.4-305.4); P=0.007). In patients, we observed a 
309 positive correlation between IGF1 levels and leukocyte counts (R0.28; P=0.02), whereas in 
310 controls, a negative correlation was present (R-0.32; P=0.04). IGF1 levels were also 
311 positively correlated with monocyte counts in patients (R0.30; P=0.01), but not in controls.
312
313 Circulating markers of inflammation and endothelial dysfunction (Figure 3)
314 In the total patient group, plasma IL18 concentrations were significantly lower than in 
315 controls (151.9 (58.6-387.4) vs. 178.5 (49.2-1528.3) pg/ml; P=0.01). IL18BP concentrations 
316 were higher in patients compared to controls (356.1 (265.6-1341.2) vs. 265.6 (265.6-601.1) 
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317 pg/ml; P<0.001). Consequently, the IL18/IL18BP ratio was significantly lower in patients 
318 than in controls (0.44 (0.11-1.29) vs. 0.65 (0.19-5.75); P<0.001); these differences were 
319 triggered by controlled patients, since uncontrolled patients did not differ from controls. 
320 VCAM1 levels were lower in patients compared to controls (320 (177-565) vs. 326 (215-561) 
321 pg/µl; P=0.008), which was caused by lower levels in controlled patients compared to 
322 controls (322 (177-565) pg/µl; P=0.003). IL18 levels correlated with VCAM1 levels (R0.514; 
323 P<0.001). The other circulating factors investigated did not differ significantly between 
324 patients and controls nor between patient subgroups.
325
326 Ex vivo cytokine production in whole blood 
327 Monocyte-derived cytokine production (Figure 4)  
328 Uncontrolled patients had higher S.aureus-stimulated IL1B production compared to 
329 controlled patients (381.6 (140-1387.9) vs. 194.8 (87.1-653.4) pg/ml; P=0.02) and higher 
330 IL1Ra production compared to controls (5847.7 (4197-11760.2) vs. 3375.9 (874.1-8797.5) 
331 pg/ml; P=0.03). Controlled patients showed a IL1B and IL1Ra production that was 
332 comparable to controls. A similar pattern was seen for IL1B and IL1Ra production in 
333 response to other WB stimuli, although these differences were not statistically significant.
334 No differences were observed in the production of monocyte-derived pro-inflammatory 
335 cytokines IL6 and TNFa between patients and controls, nor between patient subgroups. 
336
337 Th-derived cytokine production (Figure 5)
338 We found unstimulated IFNg production in patients, but not in controls (figure 5C). In 
339 addition, the S.aureus-stimulated IFNg production was significantly higher in patients 
340 compared to controls (148.1 (78-5672.7) vs. 92.7 (78-701.7) pg/ml; P=0.02); the highest IFNg 
341 production was observed in uncontrolled patients (374.4 (148.1-5389.5) pg/ml; P=0.001 vs. 
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342 controls, and P= 0.012 vs. controlled patients ((118.8 (78-5672.7) pg/ml). Again, a similar 
343 pattern was seen for the other WB stimuli. LPS-stimulated anti-inflammatory IL10 production 
344 was lower in patients compared to controls (208.1 (57.2-890.4) vs. 275.5 (74.9-1285.8) pg/ml; 
345 P=0.04). IGF1 levels positively correlated with IL6 (R0.31; P=0.008), IL1B (R0.42; 
346 P<0.001), IL1Ra (R0.51; P<0.001), and IFNg production (R0.34; P=0.004) in patients.
347
348 Subgroup – vascular measurements (Figure 6)
349 Serum lipid and IGF1 levels were not significantly different between the groups. All subjects 
350 had IGF1 levels that were in the normal reference range for age and sex.  
351 FMD was lower in patients than in controls (5.22±3.58% vs. 8.68±4.87%; P=0.06), but did 
352 not differ significantly between the patient groups. The FMD/NMD ratio was lower in 
353 patients compared to controls (0.27 (-0.08; 0.15) vs. 0.42 (0.12-5.95); P=0.04). Shear rate was 
354 lower in patients compared to controls ((15997 (4676-39954) vs. 26245 (14287-53297) AU; 
355 P=0.002). 
356 Compared to controls, patients had both a lower C_AP_HR75 (7.75±4.03 vs. 6.68±6.12 
357 mmHg; P=0.04) and PWV (9.14 (7.1-15.36) vs. 8.83 (6.63-13.46) m/s; P=0.002). When 
358 comparing patient subgroups to controls, the lower C_AP_HR75 was only present in 
359 biochemically controlled patients (5.57±5.5 mmHg; P=0.02), whereas PWV was lower in both 
360 cured (9.09 (6.63-13.27) m/s; P=0.02) and biochemically controlled patients (8.74 (7.24-13.46) 
361 m/s; P=0.03). Patients using Somatostatin analogues (SSA) had a lower C_AP_HR75 
362 (8.8±6.3 vs. 3.6±3.9 mmHg; P=0.006). IMT did not differ between controls and patients.
363
364 Discussion
365 To our best knowledge, this is the first study that comprehensively examined the multifaceted 
366 aspects of inflammation in patients with treated acromegaly and relates them to structural and 
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367 functional vascular characteristics. We hypothesized that persistent inflammation contributes 
368 to the persistence of CVD risk and the development of CVD in acromegaly patients despite 
369 adequate treatment. Indeed, we observed pro-inflammatory changes in the function of the 
370 immune system in patients with acromegaly, most pronounced in those having active disease, 
371 but partly persisting in those with controlled disease. This was paralleled by persistent 
372 endothelial dysfunction in controlled patients. These findings suggest that chronic 
373 inflammation could contribute to the high prevalence of CVD risk factors in acromegaly both 
374 during active disease as well as in adequately treated patients. 
375
376 Recent evidence suggests that IGF1 levels are related to CVD in an U-shaped fashion, with 
377 both low and high circulating IGF1 levels being associated with an increased CVD risk (34, 
378 35). Since the importance of inflammation in the development of CVD is well established (9, 
379 10), we previously investigated the effects of IGF1 in vitro. We showed direct pro-
380 inflammatory effects of IGF1 on human white blood cells in supraphysiological 
381 concentrations that reflect IGF1 levels in patients with acromegaly (18). Our group has shown 
382 long-lasting pro-inflammatory effects of IGF1 on human monocytes, a phenomenon termed 
383 ‘trained immunity’ (11). In this study we observed that acromegaly patients with active 
384 disease under treatment are characterized by high IL1B and IL1Ra as well as IFNg production 
385 capacity ex vivo in stimulated whole blood (WB). The finding that these changes in cytokine 
386 production were more pronounced in reaction to certain stimuli (i.e. all stimuli gave a similar 
387 pattern of cytokine production, but not all differences between groups were significant), 
388 suggests that the functional reprogramming of monocytes in acromegaly is selective. These 
389 pro-inflammatory changes appeared reversible after normalization of IGF1 levels, since these 
390 findings were not observed in patients with controlled disease. However, we did observe a 
391 lower production capacity of the anti-inflammatory IL10 in the total patient group, suggestive 
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392 of a pro-inflammatory change in immune cell function that persisted after normalization of 
393 IGF1 levels. In addition, WB cells produced IFNg in the absence of a stimulus in patients but 
394 not in controls, indicating a more inflammatory tendency in patients. Intriguingly, our data 
395 furthermore suggest an altered interaction between IGF1 and the immune system in 
396 acromegaly, as was reported earlier (36, 37): IGF1 levels were positively correlated with IL6, 
397 IFNg, IL1B and IL1Ra production in stimulated WB of patients, but not in WB of controls. 
398 Moreover, whereas IGF1 levels and leukocyte counts were negatively correlated in controls, 
399 we observed a positive correlation in patients. Also, the platelet-to-lymphocyte ratio was 
400 significantly higher in patients compared to controls. This inflammatory biomarker was 
401 recently shown to predict inflammatory and cardiovascular events (38). These findings are in 
402 concordance with previous reports that CVD risk decreases, but not normalizes with treatment 
403 of acromegaly (8, 39), although the prevalence of evident CVD as myocardial infarction and 
404 stroke was comparable in acromegaly patients treated in specialized centres compared to the 
405 general population (5).
406 An additional argument suggesting that acromegaly leaves a long-lasting immunological 
407 imprint is the observation that patients have lower circulating IL18 levels, paralleling higher 
408 IL18 binding protein (BP) levels. This is the first study to report on IL18 homeostasis in 
409 acromegaly. The effects of IL18 on CVD are controversial: some report IL18 to be associated 
410 with atherosclerosis, while others have shown that IL18 improves insulin sensitivity and 
411 attenuates the metabolic syndrome (40-42). These effects of IL18 are counteracted by 
412 IL18BP, which binds to IL18 and reduces the amount of free (active) IL18. The low IL18 
413 biological activity in the circulation of acromegaly patients could therefore have deleterious 
414 metabolic effects. Interestingly, IL18 induces VCAM1 expression (43), and IL18 levels 
415 strongly correlated with VCAM1 levels in our patient cohort. We found lower VCAM1 levels 
416 in controlled patients compared to controls, which raises the question whether the lower 
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417 VCAM1 levels in our cohort are a consequence of lower IL18 levels. In previous studies both 
418 similar and higher levels of VCAM1 have been reported in active acromegaly patients 
419 compared to controls (20, 44). Differences in disease activity, metabolic profiles and 
420 treatment between study populations could explain these discrepant results, since previous 
421 studies reported on untreated patients. In addition, we applied strict correction for potential 
422 confounders (age, BMI and leukocyte counts). 
423 Given the fact that the vast majority of our patients had controlled disease with normal IGF1 
424 levels, it was expected that the levels of hsCRP, which is a surrogate marker of low-grade 
425 inflammation, were not different between patients and controls. Previously, levels of hsCRP 
426 were reported to be similar in patients with controlled disease and healthy controls (3, 45).
427
428 To investigate if persistent structural and functional vascular changes could be observed after 
429 successful acromegaly treatment, and to assess the possible link between inflammation and 
430 CVD, we performed vascular measurements in a subgroup of controlled patients without 
431 hormonal deficiencies and their matched controls, a comparison that has not been previously 
432 reported. We observed impaired endothelium-dependent vascular dilatation in patients 
433 compared to controls as measured by the FMD/NMD ratio, reflecting an impairment of 
434 arterial vasoprotective functioning (46, 47). Endothelial dysfunction is considered the earliest 
435 stage of atherosclerotic disease (48), and has been reported to be present in acromegaly 
436 patients (3, 6, 33).  
437
438 Findings suggesting more advanced atherosclerosis, such as structural changes (IMT) or 
439 arterial stiffening (PWV, PWA) (47), were not observed in controlled patients. Surprisingly, 
440 our data suggested less arterial stiffness in these patients than in matched controls. A lower 
441 C_AP_HR75 was observed in biochemically controlled patients, as well as a lower PWV in 
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442 both biochemically controlled and cured patients. In contrast to our results, previous studies 
443 reported higher (49, 50) or similar PWV in patients compared to controls (32, 33, 51) and a 
444 similar (32, 33, 52, 53) or higher IMT (3, 6). These difference may be due to differences in 
445 study populations, since the aforementioned studies also included patients with active 
446 acromegaly, used non-cardiovascular matched controls or included patients using hormonal 
447 replacement therapy (3, 32, 33): all factors known to affect vascular measurements (54-56). 
448 Also, SSA – which were used by 11 out of the 14 biochemically controlled patients that 
449 underwent vascular measurements in our series – are reported to lower arterial stiffness (25). 
450 Indeed, we observed lower C_AP_HR75 values in patients using SSA. 
451 Last, we excluded patients using statins, thereby indirectly excluding those with established 
452 CVD. This has likely resulted in the inclusion of patients who are less cardiovascular and 
453 metabolic compromised, which could explain the discrepancy between our results and earlier 
454 reports.  
455
456 This study has some limitations. Our cross-sectional study showed associations between IGF1 
457 and cytokine levels and suggested that certain inflammatory and vascular changes are 
458 reversible after disease control. However, a causal relation between IGF1 excess, 
459 inflammatory and vascular changes, and the reversibility of these changes can only be 
460 assessed in a prospective manner. Second, due to the relatively small number of subjects, the 
461 statistical power of the subgroup analysis is limited and the presence of confounding factors 
462 (e.g. DM, effects of antihypertensive drugs, and hormonal deficiencies) that may influence 
463 inflammatory status cannot be ruled out. For example, serum triglyceride levels and the 
464 prevalence of DM were higher in uncontrolled patients, patients used more antihypertensive 
465 drugs and no controls had DM. When using use of antihypertensives or presence of DM as 
466 covariates in our model, no significant influence or pro-inflammatory effect of these 
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467 covariates was found, which argues against the presence of important effects of these 
468 potential confounders. However, a confounding effect cannot be completely ruled out. In 
469 addition, we observed multiple trends that need validation in larger and better matched 
470 cohorts of patients and controls. So, despite the finding that group differences were not 
471 significant, they might be clinically relevant. Third, since acromegaly has an insidious onset 
472 and is often diagnosed with a significant delay, it is usually impossible to define the exact 
473 duration of the disease or the time that patients are exposed to high IGF1 levels; these factors 
474 and previous treatments may have impacted on our outcome. Fourth, in this series we did not 
475 have information on the circulating GH levels at the time of the experiments. Although most 
476 studies have focused on the effect of IGF1 on CVD and inflammation, we cannot exclude 
477 independent effects of GH (34, 57). Finally, a significant proportion of patients used SSA, 
478 which can exert anti-inflammatory effects (58), and therefore possibly affected arterial 
479 stiffness and cytokine production in peripheral blood cells (59, 60). If this is the case, use of 
480 SSA may have alleviated some of the effects of the GH and IGF1 on systemic inflammation 
481 and vascular impairment in patients under pharmacological treatment. 
482 Although our study did not provide definitive evidence of the presence of chronic 
483 inflammation in patients with treated acromegaly, we have found several clues that point 
484 towards persistent pro-inflammatory changes in treated acromegaly patients. Further research 
485 is needed to validate our results, especially prospective studies in larger, homogeneous 
486 cohorts of patients, and research on the underlying inflammatory mechanisms that may link 
487 GH/IGF-1 excess to cardiovascular disturbances.
488
489 In conclusion, the immune profile and the interplay between IGF1 and the immune system are 
490 skewed towards inflammation in acromegaly patients who are controlled or uncontrolled 
491 under treatment. The most profound changes in the inflammatory state were found in patients 
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492 that were uncontrolled despite treatment. However, even after normalization of IGF1 levels, 
493 acromegaly appears to leave an immunological footprint. These persistent inflammatory 
494 changes could contribute to the sustained endothelial dysfunction that we observed in patients 
495 who are successfully treated and add to the development and persistence of cardiovascular 
496 risk in patients with controlled acromegaly.
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Table 1. Clinical characteristics in patients and controls. Values are displayed as mean with SD 
(standard deviation) or as median with minimum and maximum, depending on the normality of the 
distribution. Categorical variables are displayed as numbers. BMI: body mass index in kg/m2; BP: 
blood pressure; IGF1: Insulin-like Growth Factor 1; GH: Growth Hormone; Estrogen depletion (in 
women): postmenopausal women not using estrogen substitution; SSA: Somatostatin analogue; LDL: 
low-density lipoprotein; HDL: high-density lipoprotein. 
TABLE 1
Clinical characteristics
Controls (n=41) Patients (n=71) P
Sex: male 20 36 1.0
Age (years) 51.9 (14.3) 54.5 (12.1) 0.33
Height (m) 1.75 (0.09) 1.76 (0.11) 0.73
Weight (kg) 81.2 (54.8-129.8) 83.7 (51.4-150.8) 0.06
BMI (kg/m2) 27.07 (18.3-46) 27.7 (20-49.1) 0.13
Waist-to-hip ratio 0.93 (0.08) 0.94 (0.08) 0.82
Systolic BP (mmHg) 124.5 (15.1) 1298.5 (16.1) 0.9
Diastolic BP (mmHg) 75.3 (9.4) 79.680 (10.4) 0.52
Heart rate (/min) 64 (44-80) 60 (44-78) 0.87
Anti-hypertensives 3 18 0.02
Diabetes mellitus 0 8 0.03
Smoker; current/past 10/10 8/32 0.05
Alcohol use (units/week) 3 (0-20) 2 (0-21) 0.54
IGF1 (nmol/l) 17.5 (7.9-35.8) 18.2 (8.3-46.7) 0.08
Hormonal deficiency
Estrogen depletion
Hypothyroidism
Hypogonadism
Hypocortisolism
GH deficiency
Diabetes insipidus
Hyperprolactinemia
2
13
2
0
0
0
0
0
30
25
18
20
15
2
6
1
<0.001
0.56
0.01
<0.001
<0.001
0.53
0.08
0.63
Medical treatment
SSA)
Dopamin agonist
Pegvisomant
0
0
0
0
35
30
6
8
<0.001
<0.001
0.08
0.03
Surgery 0 65 <0.001
Radiotherapy
Total cholesterol (mmol/L)
HDL cholesterol (mmol/L)
LDL cholesterol (mmol/L)
Triglycerides (mmol/L)
Non-HDL cholesterol (mmol/L)
0
5.51 (1.24)
1.47 (0.51-2.84)
3.27 (1.17)
1.35 (0.58-3.55)
3.96 (1.26)
10
5.23 (1.1)
1.43 (0.57-2.88)
3.1 (0.93)
1.11 (0.53-5.46)
3.72 (1.02)
0.01
0.13
0.55
0.23
0.2
0.22
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Table 2. Clinical characteristics of patient subgroups. Values are displayed as mean with SD (standard 
deviation) or as median with minimum and maximum, depending on the normality of the distribution. 
Categorical variables are displayed as numbers; BMI: body mass index in kg/m2; BP: blood pressure; 
IGF1: Insulin-like Growth Factor 1; GH: Growth Hormone; Estrogen depletion: postmenopausal 
women not using estrogen substitution; SSA: Somatostatin analogue; LDL: low-density lipoprotein; 
HDL: high-density lipoprotein. P: P-values when comparing subgroups of controlled and uncontrolled 
patients. P*: P-values when controls are included as third subgroup in the analysis; NA: not applicable.
TABLE 2
Clinical characteristics
Controlled (n=60) Uncontrolled (n=11) P P*
Sex: male 31 5 0.75 0.93
Age (years) 56.3 (11.1) 44.6 (13.1) 0.01 0.012
Height (m) 1.76 (0.11) 1.79 (0.11) 0.61 0.66
Weight (kg) 83.2 (51.4-150.8) 111 (64.9-147.2) 0.052 0.032
BMI (kg/m2) 27 (20-49.1) 32.3 (24.1-41.4) 0.029 0.029
Waist-to-hip ratio 0.93 (0.77-1.16) 0.91 (0.82-1.04) 0.86 0.98
Systolic BP (mmHg) 129.2 (16.7) 1254.9 (13.0) 0.25 0.31
Diastolic BP (mmHg) 80.2 (10.3) 76.2 (10.4) 0.72 0.05
Heart rate (/min) 61 (44-78) 60 (56-72) 0.81 0.95
Anti-hypertensives 17 1 0.27 0.018
Diabetes mellitus 5 3 0.1 0.006
Smoker; current/past 7/27 1/5 0.67 0.97
Alcohol use (units/week) 2 (0-21) 2 (0-21) 0.56 0.69
IGF1 (nmol/l)
Disease duration (years)
17.6 (4.1)
9 (1-40)
32.6 (6.9)
3 (1-22)
0.014
0.05
<0.001
NA
Hormonal deficiency
Estrogen depletion
Hypothyroidism
Hypogonadism
Hypocortisolism
GH deficiency
Diabetes insipidus
Hyperprolactinemia
24
22
16
15
11
2
5
0
6
3
2
5
4
0
1
1
0.51
0.39
0.72
0.27
0.23
1
1
0.16
<0.001
0.66
0.012
<0.001
<0.001
0.60
0.11
0.1
Medical treatment
SSA
Dopamin agonist
Pegvisomant
28
24
4
5
7
6
2
3
0.34
0.51
0.23
0.1
NA
NA
NA
NA
Surgery 55 10 1 NA
Radiotherapy
Total cholesterol (mmol/L)
HDL cholesterol (mmol/L)
LDL cholesterol (mmol/L)
Triglycerides (mmol/L)
Non-HDL cholesterol (mmol/L)
7
5.27 (1.13)
1.47 (0.77-2.88)
3.14 (0.95)
1 (0.53-3.34)
3.70 (1.05)
3
5.05 (0.94)
1.16 (0.57-2.26)
2.88 (0.73)
1.71 (1.06-5.46)
3.83 (0.84)
0.18
0.5
0.003
0.33
0.036
0.33
NA
0.39
0.067
0.54
0.003
0.5
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 Figure 2. Leukocyte (A), lymphocyte counts (B), platelet-to-lymphocyte ratio (PtL) (C) and monocyte counts 
(D). Leukocyte en lymphocyte counts were log-transformed transformed using the natural logarithm; mean 
with SD is displayed for all parameters. 
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 Figure 3. Circulating inflammatory markers. Anti-inflammatory IL18 (A), IL18/IL18BP ratio (B), pro-
inflammatory VCAM1 (C) and pro-inflammatory E-selectin levels (D). Cytokine concentrations were log-
transformed using the natural logarithm, and mean with SD is displayed. IL18: interleukin 18; IL18BP: IL18 
binding protein; VCAM1: vascular cell adhesion molecule 1. 
172x164mm (300 x 300 DPI) 
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 Figure 4. Monocyte-derived pro-inflammatory cytokine production. LPS-stimulated TNFa (A) and IL6 
production (B), and S.aureus-stimulated IL1B (C) and IL1Ra production (D). Cytokine concentrations were 
log-transformed using the natural logarithm, and mean with SD is displayed. LPS: lipopolysaccharide; TNFa: 
tumor necrosis factor alpha; IL: interleukin; Ra: receptor antagonist 
153x152mm (300 x 300 DPI) 
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 Figure 5. Lymphocyte-derived cytokine production. S.aureus-stimulated pro-inflammatory IFNg production 
(A), LPS-stimulated anti-inflammatory IL10 production (B) and unstimulated IFNg production (C). S.aureus-
stimulated IFNg production and LPS-stimulated IL10 production were log-transformed using the natural 
logarithm. For S.aureus-stimulated IFNg production and LPS-stimulated IL10 production mean with SD is 
displayed. IFNg: interferon gamma; LPS: lipopolysaccharide; IL: interleukin. 
176x177mm (300 x 300 DPI) 
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 Figure 6. Vascular measurements. Heart rate-corrected Central Augmented Pressure (C_AP_HR75; A), PWV 
(B), FMD (C), FMD/NMD ratio (D) and IMT (E). Values were log-transformed using the natural logarithm 
prior to analysis and mean with SD is displayed. PWV: pulse wave velocity; IMT: intima-media thickness; 
FMD: flow-mediated dilatation; NMD: nitroglycerine-mediated dilatation. 
151x179mm (300 x 300 DPI) 
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